Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Essential role for orbitofrontal serotonin 1B receptors in obsessive-compulsive disorder-like behavior and serotonin reuptake inhibitor response in mice.

Shanahan NA, Velez LP, Masten VL, Dulawa SC.

Biol Psychiatry. 2011 Dec 1;70(11):1039-48. doi: 10.1016/j.biopsych.2011.07.032.

2.

Clinically effective OCD treatment prevents 5-HT1B receptor-induced repetitive behavior and striatal activation.

Ho EV, Thompson SL, Katzka WR, Sharifi MF, Knowles JA, Dulawa SC.

Psychopharmacology (Berl). 2016 Jan;233(1):57-70. doi: 10.1007/s00213-015-4086-8.

PMID:
26423528
3.

Effects of chronic fluoxetine treatment on serotonin 1B receptor-induced deficits in delayed alternation.

Woehrle NS, Klenotich SJ, Jamnia N, Ho EV, Dulawa SC.

Psychopharmacology (Berl). 2013 Jun;227(3):545-51. doi: 10.1007/s00213-013-2985-0.

PMID:
23377022
4.

Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice.

Shanahan NA, Holick Pierz KA, Masten VL, Waeber C, Ansorge M, Gingrich JA, Geyer MA, Hen R, Dulawa SC.

Biol Psychiatry. 2009 Mar 1;65(5):401-8. doi: 10.1016/j.biopsych.2008.09.026.

5.

Stereotypic behaviour in the deer mouse: pharmacological validation and relevance for obsessive compulsive disorder.

Korff S, Stein DJ, Harvey BH.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Feb 15;32(2):348-55.

PMID:
17888556
6.

Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder.

El Mansari M, Blier P.

Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):362-73. Review.

PMID:
16427729
8.

Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.

Humble MB, Uvnäs-Moberg K, Engström I, Bejerot S.

BMC Psychiatry. 2013 Dec 23;13:344. doi: 10.1186/1471-244X-13-344.

9.

Neurosteroids modulate compulsive and persistent behavior in rodents: implications for obsessive-compulsive disorder.

S N U, J M V, N S J, P V D.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Oct 1;33(7):1161-6. doi: 10.1016/j.pnpbp.2009.06.013.

PMID:
19549549
10.

Ritualistic chewing behavior induced by mCPP in the rat is an animal model of obsessive compulsive disorder.

Kreiss DS, Coffman CF, Fiacco NR, Granger JC, Helton BM, Jackson JC, Kim LV, Mistry RS, Mizer TM, Palmer LV, Vacca JA, Winkler SS, Zimmer BA.

Pharmacol Biochem Behav. 2013 Mar;104:119-24. doi: 10.1016/j.pbb.2013.01.006.

PMID:
23333679
11.

Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.

Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, McElroy S, Zajecka J, Chapman D, Clary C, Harrison W.

Arch Gen Psychiatry. 2000 Jan;57(1):76-82.

PMID:
10632236
13.

OCD: where the serotonin selectivity story begins.

Pigott TA.

J Clin Psychiatry. 1996;57 Suppl 6:11-20. Review.

PMID:
8647793
14.

Age differences in the sensitivity to clomipramine in an animal model of obsessive-compulsive disorder.

Fernández-Guasti A, Ulloa RE, Nicolini H.

Psychopharmacology (Berl). 2003 Mar;166(3):195-201.

PMID:
12589517
15.

Neurobiology and clinical pharmacology of obsessive-compulsive disorder.

Micallef J, Blin O.

Clin Neuropharmacol. 2001 Jul-Aug;24(4):191-207. Review.

PMID:
11479390
16.

Issues in the pharmacological treatment of obsessive-compulsive disorder.

Math SB, Janardhan Reddy YC.

Int J Clin Pract. 2007 Jul;61(7):1188-97. Review.

PMID:
17511795
17.
18.

A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder.

Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E.

Am J Psychiatry. 2008 May;165(5):621-30. doi: 10.1176/appi.ajp.2007.07091440.

19.

Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.

Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH.

Am J Psychiatry. 1997 Sep;154(9):1293-5.

PMID:
9286191
20.

[Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].

Nakamae T.

Seishin Shinkeigaku Zasshi. 2011;113(10):1016-25. Review. Japanese.

PMID:
22187889
Items per page

Supplemental Content

Support Center